Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study
Obesity · 2025
DOI: 10.1002/oby.24306 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2025. Verfasst von Lin Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Metabolic Syndrome, Obesity, Triglycerides. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
The objective of this study was to evaluate the association of tirzepatide with body weight, cardiometabolic markers, and metabolic syndrome in Chinese participants achieving normal body mass index (BMI) values by week 52 across baseline BMI subgroups.
Methods
This post hoc analysis of SURMOUNT‐CN assessed the association of tirzepatide with cardiometabolic risk factors in Chinese participants, categorized by Chinese‐specific anthropometric cutoffs for BMI and waist circumference. The association of early weight loss (greater or less than median at 12 and 24 weeks) with cardiometabolic markers and metabolic syndrome was evaluated.
Results
In this post hoc analysis ( N = 177; tirzepatide 10 mg, n = 62; tirzepatide 15 mg, n = 57; placebo, n = 58), participants with greater weight reduction (greater than or equal to the median percentage loss at 12 and 24 weeks) showed significantly greater improvements in cardiometabolic markers. Tirzepatide also significantly reduced body weight, BMI, and waist circumference compared with placebo ( p < 0.05). At week 52, 37 participants achieved a normal BMI (18.5–24 kg/m 2 , Chinese criteria), and metabolic syndrome dropped from 21.6% at baseline to 0%.
Conclusions
Early weight loss with tirzepatide was associated with significant improvements in cardiometabolic risk factors, particularly in Chinese adults achieving a normal BMI by week 52, suggesting that early response may be associated with enhanced long‐term metabolic health outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zhongshan Hospital, Fudan University, Shanghai, China.
- Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
- The First Affiliated Hospital of Henan University of Science and Technology, Henan, China.
- The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Beijing Tsinghua Changgung Hospital, Beijing, China.
ORCID-Profile: Yuanyuan Li, Xiaoying Li
Förderung
- Eli Lilly and Company
Zitieren
APA
Zhao, L., Chen, H., Cheng, Z., Jiang, H., Lu, Y., Xiao, J., Xiao, X., Li, Y., Yuan, Y., & Li, X. (2025). Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study. Obesity. https://doi.org/10.1002/oby.24306
Vancouver
Zhao L, Chen H, Cheng Z, Jiang H, Lu Y, Xiao J, et al. Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study. Obesity. 2025. doi:10.1002/oby.24306
BibTeX
@article{Zhao2025,
author = {Zhao, Lin and Chen, Hong and Cheng, Zhifeng and Jiang, Hongwei and Lu, Yibing and Xiao, Jianzhong and Xiao, Xinhua and Li, Yuanyuan and Yuan, Yuan and Li, Xiaoying},
title = {Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT ‐ CN study},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24306}
}
EUVIMED